Last chance to benefit from reduced registration fees!
Final Early-Bird deadline – September 15

This is our final Early-Bird extension! Don’t miss the opportunity to attend the Europe Biobank Week 2021 at a discounted rate. Our early bird pricing offer will end tomorrow – Wednesday, 15th September.

Join #EBW21 to engage and share knowledge with the global biobanking community, enjoy all the scientific insights from speakers and panellists and network around this year’s theme “Biobanking for our Future – Opportunities Unlocked”.

Top reasons to attend:

•20+ high quality sessions covering the most current research, biobanking best-practices, and industry trends
•30+ top-notch presenters, carefully selected by Session Chairs
•Unique networking opportunities
•Workshops by our sponsors on the latest biobanking and biomedicine topics
and much more…

Professor Sherene Loi, internationally recognized as a leading clinician scientist, to speak on the ‘Importance of Biobanking for Breast Cancer Translational Research’
Don’t miss the Europe Biobank Week 2021
Keynote Address

Join us for the Keynote address by Professor Sherene Loi, MBBS (Hons), PhD, FRACP, FAHMS.

Professor, University of Melbourne.
Consultant Medical Oncologist, Breast Unit.
Breast Stream Lead, Parkville Cancer Clinical Trials Unit (PCCTU).
Head, Translational Breast Cancer Genomics and Therapeutics Lab.
National Breast Cancer Foundation of Australia Endowed Chair.

“Importance of Biobanking for Breast Cancer Translational Research”

Session date & time:
Wednesday, 10 November 2021
11:30 – 12:30 CET
Professor Sherene Loi is a Medical Oncologist specialized in breast cancer treatment as well as a clinician scientist with expertise in genomics, immunology and drug development. Professor Loi is recognised internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology field.

After completing Medical Oncology specialist clinical training in Melbourne, she undertook a PhD and postdoctoral studies at the Institut Jules Bordet in Brussels, Belgium. In 2013, Sherene returned to a Group Leader position at the Peter MacCallum Cancer Centre in Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit.

To date, Professor Sherene Loi has published over 250 peer-reviewed research articles with a lifetime H index of 84. Her recent work has been highly influential with 36,500 total citations and 27,531 (75%) within the past 5 years. She is ranked in the top 1% of highly cited researchers globally by the Web of Science since 2018. Sherene is a Board Director as well as a member of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (BCT Australia/NZ), which is the largest breast cancer clinical trials cooperative group in Australia. She is Co-Chair the Scientific Executive Committee of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries. Sherene Loi is the current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and a research fellow of the Breast Cancer Research Foundation (BCRF), New York.